- Home
- QTWO vs GH Comparison
QTWO vs GH Comparison
Compare QTWO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTWO
- GH
- Stock Information
- Founded
- QTWO 2004
- GH 2011
- Country
- QTWO United States
- GH United States
- Employees
- QTWO N/A
- GH N/A
- Industry
- QTWO Computer Software: Prepackaged Software
- GH Medical Specialities
- Sector
- QTWO Technology
- GH Health Care
- Exchange
- QTWO Nasdaq
- GH Nasdaq
- Market Cap
- QTWO 4.8B
- GH 4.7B
- IPO Year
- QTWO 2014
- GH 2018
- Fundamental
- Price
- QTWO $95.47
- GH $45.13
- Analyst Decision
- QTWO Buy
- GH Strong Buy
- Analyst Count
- QTWO 16
- GH 14
- Target Price
- QTWO $95.56
- GH $39.93
- AVG Volume (30 Days)
- QTWO 610.4K
- GH 1.9M
- Earning Date
- QTWO 02-19-2025
- GH 02-20-2025
- Dividend Yield
- QTWO N/A
- GH N/A
- EPS Growth
- QTWO N/A
- GH N/A
- EPS
- QTWO N/A
- GH N/A
- Revenue
- QTWO $675,537,000.00
- GH $692,256,000.00
- Revenue This Year
- QTWO $13.23
- GH $32.21
- Revenue Next Year
- QTWO $11.35
- GH $16.90
- P/E Ratio
- QTWO N/A
- GH N/A
- Revenue Growth
- QTWO 10.92
- GH 29.20
- 52 Week Low
- QTWO $40.60
- GH $15.81
- 52 Week High
- QTWO $112.82
- GH $45.66
- Technical
- Relative Strength Index (RSI)
- QTWO 43.97
- GH 79.68
- Support Level
- QTWO $86.56
- GH $36.45
- Resistance Level
- QTWO $96.12
- GH $39.29
- Average True Range (ATR)
- QTWO 3.30
- GH 2.35
- MACD
- QTWO -0.62
- GH 0.75
- Stochastic Oscillator
- QTWO 51.92
- GH 96.63
About QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.